Literature DB >> 25766596

Targeting FcRn for the modulation of antibody dynamics.

E Sally Ward1, Siva Charan Devanaboyina2, Raimund J Ober3.   

Abstract

The MHC class I-related receptor, FcRn, is a multitasking protein that transports its IgG ligand within and across cells of diverse origins. The role of this receptor as a global regulator of IgG homeostasis and transport, combined with knowledge of the molecular details of FcRn-IgG interactions, has led to opportunities to modulate the in vivo dynamics of antibodies and their antigens through protein engineering. Consequently, the generation of half-life extended antibodies has shown a rapid expansion over the past decade. Further, FcRn itself can be targeted by inhibitors to induce decreased levels of circulating IgGs, which could have applications in multiple clinical settings. The engineering of antibody-antigen interactions to reduce antibody-mediated buffering of soluble ligand has also developed into an active area of investigation, leading to novel antibody platforms designed to result in more effective antigen clearance. Similarly, the target-mediated elimination of antibodies by internalizing, membrane bound antigens (receptors) can be decreased using novel engineering approaches. These strategies, combined with subcellular trafficking analyses of antibody/antigen/FcRn behavior in cells to predict in vivo behavior, have considerable promise for the production of next generation therapeutics and diagnostics.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody engineering; FcRn; IgG; Pharmacokinetics; Therapeutic antibodies; pH-dependence

Mesh:

Substances:

Year:  2015        PMID: 25766596      PMCID: PMC4529761          DOI: 10.1016/j.molimm.2015.02.007

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  147 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

2.  Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.

Authors:  Jasmine P Davda; Ryan J Hansen
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

3.  Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway.

Authors:  Zhuo Gan; Sripad Ram; Raimund J Ober; E Sally Ward
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

Review 4.  Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer.

Authors:  Robert Goldstein; Jane Sosabowski; Kim Vigor; Kerry Chester; Tim Meyer
Journal:  Expert Rev Anticancer Ther       Date:  2013-03       Impact factor: 4.512

5.  The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans.

Authors:  M Firan; R Bawdon; C Radu; R J Ober; D Eaken; F Antohe; V Ghetie; E S Ward
Journal:  Int Immunol       Date:  2001-08       Impact factor: 4.823

6.  Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells.

Authors:  Kristi Baker; Shuo-Wang Qiao; Timothy T Kuo; Victoria G Aveson; Barbara Platzer; Jan-Terje Andersen; Inger Sandlie; Zhangguo Chen; Colin de Haar; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

7.  Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs.

Authors:  Balázs Mayer; Anna Zolnai; László V Frenyó; Veronika Jancsik; Zoltán Szentirmay; Lennart Hammarström; Imre Kacskovics
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

8.  Mouse MHC class I-like Fc receptor encoded outside the MHC.

Authors:  J J Ahouse; C L Hagerman; P Mittal; D J Gilbert; N G Copeland; N A Jenkins; N E Simister
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

9.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestine.

Authors:  Mark S Ladinsky; Kathryn E Huey-Tubman; Pamela J Bjorkman
Journal:  Mol Biol Cell       Date:  2012-05-09       Impact factor: 4.138

View more
  32 in total

1.  Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

Authors:  Felix Unverdorben; Fabian Richter; Meike Hutt; Oliver Seifert; Pauline Malinge; Nicolas Fischer; Roland E Kontermann
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 2.  In vivo imaging with antibodies and engineered fragments.

Authors:  Amanda C Freise; Anna M Wu
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

Review 3.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

4.  Engineering a human IgG2 antibody stable at low pH.

Authors:  Seiji Saito; Hiroshi Namisaki; Keiko Hiraishi; Nobuaki Takahashi; Shigeru Iida
Journal:  Protein Sci       Date:  2020-03-18       Impact factor: 6.725

Review 5.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

6.  Engineering therapeutic antibodies to combat infectious diseases.

Authors:  Ellen K Wagner; Jennifer A Maynard
Journal:  Curr Opin Chem Eng       Date:  2018-03-07       Impact factor: 5.163

Review 7.  Selecting and engineering monoclonal antibodies with drug-like specificity.

Authors:  Charles G Starr; Peter M Tessier
Journal:  Curr Opin Biotechnol       Date:  2019-02-26       Impact factor: 9.740

Review 8.  Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.

Authors:  Dhuha H Nawab
Journal:  Hum Vaccin Immunother       Date:  2021-11-29       Impact factor: 3.452

9.  Recombinant Proteins and Monoclonal Antibodies.

Authors:  Roy Jefferis
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 10.  Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.

Authors:  Franziska Bootz; Dario Neri
Journal:  Drug Discov Today       Date:  2015-10-23       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.